Insights into dengue immunity from vaccine trials
Eng Eong Ooia b c✉, Shirin Kalimuddina d
- aProgram in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore
- bSaw Swee Hock School of Public Health, National University of Singapore, Singapore 117549, Singapore
- cViral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore 169857, Singapore
- dDepartment of Infectious Diseases, Singapore General Hospital, Singapore 169856, Singapore
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
The quest for an effective dengue vaccine has culminated in two approved vaccines and another that has completed phase 3 clinical trials. However, shortcomings exist in each, suggesting that the knowledge on dengue immunity used to develop these vaccines was incomplete. Vaccine trial findings could refine our understanding of dengue immunity, because these are experimentally derived, placebo-controlled data. Results from these trials suggest that neutralizing antibody titers alone are insufficient to inform protection against symptomatic infection, implicating a role for cellular immunity in protection. These findings have relevance for both future dengue vaccine development and application of current vaccines for maximal public health benefit.
TL;DRResults from these trials suggest that neutralizing antibody titers alone are insufficient to inform protection against symptomatic infection, implicating a role for cellular immunity in protection. (Semantic Scholar)